ASCLF (Ascletis Pharma) Gross-Profit-to-Asset % : 0.00% (As of Jun. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Ascletis Pharma Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Ascletis Pharma's annualized Gross Profit for the quarter that ended in Jun. 2024 was $0.00 Mil. Ascletis Pharma's average Total Assets over the quarter that ended in Jun. 2024 was $331.30 Mil. Therefore, Ascletis Pharma's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2024 was 0.00%.

Ascletis Pharma Gross-Profit-to-Asset % Historical Data

The historical data trend for Ascletis Pharma's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascletis Pharma Gross-Profit-to-Asset % Chart

Ascletis Pharma Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

3.54

-0.75

1.35

-0.86

1.00

Ascletis Pharma Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial											1.68	-3.51	2.87	-0.98	-

Competitive Comparison of Ascletis Pharma's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Ascletis Pharma's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ascletis Pharma's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascletis Pharma's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Ascletis Pharma's Gross-Profit-to-Asset % falls into.

Ascletis Pharma Gross-Profit-to-Asset % Calculation

Ascletis Pharma's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	3.64	/	( (381.118	+	348.871)	/ 2 )
	=	3.64	/	364.9945
	=	1.00 %

Ascletis Pharma's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Jun. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Jun. 2024 ))	/ count )
	=	0	/	( (348.871	+	313.736)	/ 2 )
	=	0	/	331.3035
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Jun. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Ascletis Pharma Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Ascletis Pharma's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Ascletis Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascletis Pharma Inc (OTCPK:ASCLF) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

01672:Hong Kong 2VJ:Germany

Address

198 Qidi Road, 12th Floor, Building D, HIPARK, Xiaoshan District, Zhejiang Province, Hangzhou, CHN, 311200

Website

https://www.ascletis.com

Ascletis Pharma Inc is an investment holding company. Along with its subsidiaries, it is engaged in the research and development, production, marketing, and sale of pharmaceutical products. It has three marketed products, i.e. Ritonavir tablets, GANOVO, and ASCLEVIR. It also has other drug candidates in its pipeline in their different stages of development such as ASC22, ASC10, ASC11, and ASC40 among others. Geographically, it operates in Mainland China and other countries.